|Name||Position||Country||Term||Time in Office|
|H. Morris||Chair||AU||2nd||2015 01 - 2017 12|
|C. Cooper||Co Chair - International Osteoporosis Foundation|
|M. Munk||Corp. Rep/IDS|
|B. Ofenloch Haehnle||Corp. Rep./Roche|
|S. Silverman||National Bone Health Alliance (NBHA)|
To standardize or harmonize (as technically feasible or appropriate at this time) clinical assays available for routine and research use, for the following two bone turnover markers; the serum assay for C-telopeptide fragments of collagen type I a1 chains containing the epitope Glu-Lys-Ala-His-Asp-ß-Gly-Gly-Arg in an isomerised form (also known as serum Crosslaps (CTx)) and the serum assay for N-terminal Propeptide of Type I Procollagen (P1NP).
Review literature and current status of available assays in order to develop and undertake a project to establish a reference measurement system for serum β-CTx or harmonisation of the assays for serum β-CTx as appropriate.
Review literature and current status of available assays in order to develop and undertake a project to establish a reference measurement system for serum P1NP or harmonisation of the assays for serum P1NP as appropriate.
Review and identify data required for the regulatory authorisation of these modified assays.
Review literature and consider the critical decision limits and potential target levels of serum β-CTx and serum P1NP for treatment of postmenopausal osteoporosis and other causes of osteoporosis as appropriate
|Name||Full and Affiliate Member Societies|
|Masakazu Miura||Japan Society of Clinical Chemistry (JSCC)|
|Elaine Azinge||Association of Clinical Chemists Nigeria (ACCN)|
|Aylin Sepici Dincel||Turkish Biochemical Society (TBS)|
Prof. Howard MORRIS
Chemical Pathology Directorate, SA Pathology
BOX 14 Rundle Mall Post Office
Tel.: +61 423780759
Fax: +61 8 8222 3518